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Perspectives on the RiskAssessment for
Nongenotoxic Carcinogens and Tumor
Promoters
by Frederica PR Perera*
Theissueofriskassessmentforcarcinogensthatappeartoactvianongenotoxic mechanismsoratthetumorpromo-
tionstage, respectively, isdiscussedinlightofcurrentinformationonbiologicalmechanismsinvolvedincarcinogenesis
aswell asinterindividual variability inhumanresponse. Proposals totreat "nongenotoxic"carcinogens andtumorpro-
motersasposinglowerriskstohumansaredescribedandevaluated. Itisconcludedthat, forpurposesofriskassessment
andregulation, there iscurrently noconvincingscientificrationaleforconstructingcategoriesofcarcinogensaccording
to their presumed mechanism orstageofaction.
Introduction
Beforetacklingthequestion, Whyisriskassessmentfor"non-
genotoxic" andtumor-promotingcarcinogenssuchanimportant
and controversial issue, let me stress that the two terms are not
synonymous. Rather, they reflect presumptions ofmechanism
("nongenotoxic") and stage of operation (tumor promoter).
Nevertheless, although the two classes are not congruent, they
overlapinthat manyofthe samechemicalshavebothcharacter-
istics. Thus,thisreviewtreatsthemasposingseparatebutrelated
questions. By way ofbackground, a significant numberofcar-
cinogens areinactive oronlyweaklyactiveinconventional tests
forgenotoxicity such as assays forcovalentbindingtoDNAand
induction ofmutagenicity in Salmonella (1). For example, an
estimated33%ofthe 138rodentcarcinogenstestedbytheNational
Toxicology Program(NTP) werenegativeintheAmesassayand
werealsonegative forstructural alerts toDNAreactivity (2,3).
These carcinogens include commercially important industrial
chemicalsandman-madesubstancesthatrepresentsignificanten-
vironmental and occupational hazards by virtue of their high
volumeofproductionandreleasetotheenvironment. Examples
arehalogenated organiccompoundsused aspesticidesandher-
bicides, polychlorinated biphenyls, and asbestos. At the same
time, anumberofcommerciallyvaluablecompounds,suchassac-
charin, phenobarbital, anddi(2-ethylhexyl)phthalate, areinac-
tive or weak initiating carcinogens but are capable ofacting as
tumorpromotersinexperimentalsystems.Therefore,debatesover
theextentofriskposedbysuchagentsreadilybecomepoliticized.
The mechanisms by which nongenotoxic compounds and
tumor promoters induce cancer are less well understood than
those for carcinogens that directly damage DNA. Despite a
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recentproliferation ofresearch, themajorfocus inexperimen-
talandhumansystemshasbeenonmechanismsbywhichmodel
genotoxicagentsexerttheireffectsduringtheinitiationandpro-
gression stages of chemical carcinogenesis. In the area of
biomonitoring, forexample, abatteryofbiologicmarkersiscur-
rentlybeingvalidatedtoinvestigatethesemechanisms inin vitro
studies, inlaboratoryanimalsandinhumans(4,5)(Table 1). By
contrast, therearemarkedly fewerbiologicmarkersthatenable
theparallelevaluationinexperimental systemsandinhumansof
nongenotoxic orindirectgenotoxicmechanisms involvedincar-
cinogenesisandofmechanisms specific tothepromotion stage.
Thisisasignificantgapinresearchthatmayeventuallybefilled
bybiologicmarkerssuchasthosereflectingindirectgenetictoxi-
city (e.g., oxidativedamage)andmoleculareventsintumorpro-
motion (e.g., increased expression ofcertain genes implicated
in growth control). For example, experimentally, 12-0-tetra-
decanoylphorbol-13-acetate (TPA) and other tumor promoters
causeincreasedexpressionofgenesrelatedtocellproliferation,
includingc-mycandc-fos, ornithinedecarboxylase(ODC), and
phorbin (phorbol ester inducible gene), possibly as a resultof
bindingtoandactivatingproteinkinaseC(PKC)(6). Research
is now underway to determine whetherthe human homolog of
phorbin, erythroidpotentiatingactivity (EPA), canbeusedas a
biomarker inhumans exposed to tumorpromoters.
This greatmeasure ofbiologic uncertainty concerning non-
genotoxiccarcinogensandtumorpromotersquitenaturally leads
to heightened controversy. In this and in other such debates
involving scientific uncertainty, there is a thin line between
science and policy, with values playing a central, often unac-
knowledged, role (7). Thus, during the past decade, we have
seen the evolution oftwo diametrically opposed views on the
subject of risk assessment for carcinogens. The first is that
nongenotoxic agents and tumor promoters are likely to have
thresholds and therefore present less risk to humans thanF P PERERA
Ikble 1. Moleculareffects usedas biomarkers.
System
Biomarker Laboratory Human
Genotoxic carcinogens
Covalent binding to DNA I V
DNA repair V V
Gene mutation V V
Chromosomal aberration V V
Oncogene activation V V
Nongenotoxic carcinogens'
PKC induction
Phorbin/EPA induction V
ODC induction V
Cell-to-cell communication V
Oncogene overexpression V
'PKC, proteinkinaseC; ODC, omithinedecarboxylase; EPA, erythroidpo-
tentiating activity.
genotoxic orinitiatingcarcinogens (8-10) and, conversely, that
nongenotoxic agentsand promoters areofparticular concern in
terms ofhuman risk (11-14).
The first position is based upon the assumption that unless
agents areable todamage DNA and mutate genes, they cannot
beconsidered to exertlow-doselinearity. Theoppositeposition
holdsthatthereis noreliableevidenceofthepresence orabsence
of an experimental or human threshold for any carcinogen
regardless ofits mechanism or stage ofaction (14,15) and that
rapid benefits in terms of human cancer prevention can be
achievedbycontrolling exposure tonongenotoxicandpromoting
agents (11,14). Theseauthors citethedrasticreductioninhuman
cancerachievedthroughcontrolofcigarette smoking(both anin-
itiatorand apromoter) and exposure toestrogen(believedtoact
as apromoter) (11).
Traditionally, the major U.S. Federal and State agencies
have used a nonthreshold model in risk assessment for car-
cinogens-regardless oftheir presumed mechanism ofaction
(16). This decision has rested largely on two key assumptions,
which were necessitated by the uncertainty about the true dose-
response in humans. The first is that risk from any individual
carcinogen will be at least additive upon background; the se-
cond assumption is that it is impossible to identify a threshold
for a heterogeneous human population given the possible wide
interindividual variability in response to carcinogens.
In 1984, I reviewed the literature pertaining to risk assess-
ment for nongenotoxic agents in light of several proposals to
amend Federal cancer policy by treating the agents as thresh-
old-type toxicants (17). While many scientists shared the
desire to fine tune the risk assessment process to make it more
mechanistically relevant, the consensus at that time was that
such proposals were premature given the current state of
knowledge (17). This paper is intended to update that earlier
review by assessing new information developed in the interven-
ing 5-year period.
Chronology of Events
To recapitulatebriefly, in 1980-1981,WilliamsandWeisburger
(8,9) proposed that "epigenetic/nongenotoxic" carcinogens
(defined as thosenegative inthe Ames assay, thehypoxanthine
[quanine] phosphoribosyl transferase [HPRT] gene mutation
assay, therodenthepatocyte assay forDNAdamageandrepair,
andtheassayforsisterchromatidexchange)werelikelytohave
thresholdsandcouldberegulatedlessstringentlythangenotoxic
carcinogens. AsimilarviewwasalsoespousedbyStottetal. (18),
whosingledoutDNAalkylationin vivoandDNArepairastests
forgenotoxicity. TheEnvironmental Protection Agency (EPA)
(19)proposedtoamenditsexistingcancerpolicyby stipulating
thatonly "genotoxic" carcinogens (thosehavingpositiveresults
inseveralassaysforgenemutation)wouldberegulatedusingthe
no-threshold linearized model. The no-observed-effect level
(NOEL) safety-factorapproachpreviouslyreservedfornoncar-
cinogens wouldbe applied to all others. Thepractical effectof
thispolicy changewouldhavebeenarelaxationofstandards for
certainwaterbornecarcinogens by 100-to 1000-foldcompared
tostandardsdevelopedusingthetraditional linearriskextrapola-
tion approach (17). After receiving overwhelmingly critical
comments fromthescientific community, EPAdid notfinalize
the proposal.
Concurrently, theCaliforniaDepartmentofHealth Services
(15)carriedoutasimilardeliberationandconcluded: "Low dose
linearity appliesequallywelltoagentswhicharethoughttoact
by either genetic or epigenetic mechanisms ifone makes the
reasonable assumption that similar mechanisms are already
operating and contributing to the background incidence of
cancer."
Similarly, working groups of the International Agency for
ResearchonCancerconcluded in 1983 (andagainin 1987) that
therewasinsufficientinformationtoimplementaclassification
ofagentsaccording totheirmechanismofaction (20,21). This
doesnotmean,however, thatthescientificcommunityhasbeen
unanimousonthisquestion. In 1983, KroesfromtheNetherlands
(10) wrote:
Currentknowledgedoesnotpermitarigidclassificationofcarcinogens, but
doeswarrantasubclassification intogenotoxicandnongenotoxiccompounds.
Whereas forgenotoxic compounds areal thresholdcannotbeexpectedon a
theoretical basis, the existence of a threshold may well be expected for
nongenotoxiccompounds. Inconjunctionwithothercharacteristics itmaythen
bedecidedwhetheragenotoxic or nongenotoxic compound may be or may
notbe permitted inthe human environment.
Two years later, in 1985, the Office of Science and Tech-
nology Policy (OSTP) grappled with this question in compil-
ing an interagency review ofthe science regarding risk assess-
ment for carcinogens (22). The report stated: "At the present
state of knowledge mechanistic considerations such as DNA
repair and other biologic responses, in general, do not prove
the existence of, or the absence of, or the location ofa thres-
hold for carcinogenesis."
The EPA cancer policy, revised in 1986 (23), was consistent
with OSTP in stating that: "At present, mechanisms ofthe car-
cinogenesis process are largely unknown and data are general-
ly limited... In the absence of adequate information to the
contrary, the linearized multistage model will be employed."
More recently, in 1989, the EPA has solicited comments
from outside reviewers on the question ofhow to use mechan-
istic information relating to factors such as hormonal car-
cinogenesis, the role of cellular peroxide formation and
cytotoxicity, promotion and, very importantly, genotoxicity
(24). Thus, this is a recurrent theme that deserves serious fur-
ther consideration by the scientific community.
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Definitional Problems in Formulating
Separate RiskAssessmentStrategies
for Nongenotoxic Carcinogens and
Tumor Promoters
Thefirstquestionisthedefinitionoftheterm "nongenotoxic."
Majorconfusionhasarisenbecausenongenotoxiccarcinogens
arefrequently, andmistakenly, equatedwith tumorpromoters,
andgenotoxic carcinogens areoftentreatedsynonomouslywith
initiating agents. Asdiscussedby Yamasaki (14), theterms "in-
itiation" and "promotion" refer to stagesofoperation, usually
inthe two-stageexperimental modelofcarcinogenesis, whereas
genotoxicity andnongenotoxicity refer topossiblemechanisms
bywhich agents exerttheireffects. Thereis no consensusinthe
scientificcommunity astothecriteriaforgenotoxicity. Thishas
led individual researchers to define these criteria arbitrarily.
Thus, at one end ofthe spectrum the term has been narrowly
defined as "positive in the Ames assay" while atthe other ex-
treme is the broadest definition, which includes the ability,
directly or indirectly, to damage or alter the genetic material
(17,25,26). Inbetween arepermutations showninTable2, which
well illustrate the arbitrary nature ofthe exercise.
Inaddition, itismisleading to usethese terms to suggestthat
achemical actsonly via agenotoxic ornongenotoxicmechanism
(14,27). Forexample, polycyclicaromatichydrocarbons (PAHs)
arebothgenotoxic(bindingcovalently toDNA)andnongenotox-
ic(modulatingmembranereceptors) (28). Moreover, eachofthe
carcinogens shown inTable3 labeled "nongenotoxic" byvarious
investigators (1,8,9) has displayed some genetic toxicity. Al-
thoughin most cases, themajorityofshort-term testresultshave
beennegative, eachhasbeenpositivein assays forchromosomal
aberrations, sisterchromatidexchange(SCE)and/orgenemuta-
tion, possibly as a result of induction of reactive superoxide
radicals (25,29,30). It is generally agreed that the induction of
chromosomal aberrations, SCEs, or gene mutation in well-
designed, carefully controlled studies can provideevidence of
genetictoxicity. A moststriking findinghasbeentheinduction
ofanovelactivatingpointmutationin the ras oncogenebyfuran
and furfural, both of which are negative in the Ames assay
(31,32).
Similarly, the term "tumor promoter" has been subject to
widelyvaryingdefinitions. Thetermis anoperational one, refer-
ring toactivity inthe two-stageexperimentalmodel (usually in
mouseskinorratliver) inwhichtheagentinquestiondoes not,
by itself, significantly increase tumorformationbut, when ad-
ministered after an initiating agent or complete carcinogen,
significantly enhances the induction oftumors. These studies
have suggested that initiating agents directly interact with the
genetic apparatus ofcells, whereas the promoting agents en-
couragethese latentinitiated cells toexpandclonally and form
Table2. Ddinitions ofgenotoxicity.
Criteria Reference
Mutagenicity (Ames, HPRT), DNAdamage/repair, and (8,9)
sister chromatid exchange
DNA alkylation in viw and DNA repair (18)
Gene fhutation: two assays, oneeukaryotic or one whole (19)
mammal test
Direct or indirect genomic changes (14,17,25,26)
TIble36 Nongenotoxiccarcinogenswith someevidenceofgenetictoxicity.
Agente Endpoint/system Reference
TCE Mutation/bacteria andanimalcells; (51)
SCE/humancells invtrob
DDT Chromosomal aberrations/human cells in vivo (52)
Mutation/animal cells in viw (51)
Ethyl alcohol SCEandchromosomal aberrations/human (51,53)
cells in vivo
Asbestos SCE andchromosomal aberrations/human (54)
cells in vivo
TPA SCEandchromosomal aberrations/human (25)
cells in vitro
Furanand Pbint mutation in rasoncogene/rodent in vio (31,32)
furfural
WCE, trichloroethylene; TPA, 12-0-tetradecanoylphorbol-13-acetate.
'SCE, sisterchromatid exchange.
a benign tumor (4,14,33-35). During the past several years,
evidencehasdevelopedthatsometypeofheritableimprinting is
also involved in tumor promotion, possibly via an indirect
geneticmechanism(14,25,33,35-39). Recentstudiesindicatethat
tumor promoters can induce genomic changes-albeit indi-
rectly-throughinductionoffreeradicalsandsuperoxidesthat
reactwith DNA andcausemolecularlesions (such asthymine
glycol and other altered nucleic acid structures)
(4,17,26,33,41,42). Thus, indirect genotoxicity has been im-
plicated in the induction ofchromosomal aberrations by TPA
(25) and in the formation of DNA strand breaks in human
leukocytesbybenzoylperoxide, anotherpotenttumorpromoter
(43).
In addition, the terms "initiator" and "promoter" are not
mutuallyexclusive. Manycarcinogens canactasbothinitiators
andpromotersinthe sametissueororgan. Forexample, PAHs
act as completecarcinogens on mouse skin andtherefore have
bothtypesofactivity. TPA, whichisapotentpromoterinmouse
skin, alsoactsasaweakcompletecarcinogeninthattissue(14).
Therearealsonumerousexamplesofagentsthatcanactatdif-
ferentstagesindifferentorgans. Urethane(ethylcarbamate) is
notacompletecarcinogeninmouseskin,althoughitisaneffec-
tiveinitiator. Inmouseliver,however, urethaneisacompletecar-
cinogen, presumablybecausecelldivisionintheliveractsasan
effectivepromotionalstimulus(33). Inhumans,asbestosappears
toactasapromotingagentor, atleast, a"late-stage" carcinogen
inlungcancerandas aninitiating agentinmesothelioma (20).
Forall thesereasons, BarrettandWiseman (33) haveconclud-
ed that one cannot predict the tumorigenicity ofa compound
based on itsability to actas apromoter in atwo-stage model.
Regardingthequestionofdose-responsefortumorpromoters,
ithasbeennotedthatapparentdose-responsethresholds inex-
perimentalsystemsmayactuallyreflectdose-schedulethresholds
(14,39,44-46). Interestingly, in the mouse skin model and in a
two-stagein vitr celltransformationsystem, respectively, treat-
mentbybenzo[aJpyreneorX-raysalonedidnotgivealineardose
response. Linearity wasseenonlyinthepresenceofthetumor-
promoting agent TPA (14,47,48). These results suggest that
availableexperimentaldatashowadose-scheduleeffect, notto
beconfusedwithathreshold, andthatlow-doselinearity ofin-
itiatingagentsmayinsomecasesdependuponexposuretopro-
moting agents.
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Table 4. Interindividual variation inhumancells(4,5556).
Process Maximum observed variation
Absorption/transport ?
Activation/deactivation
P-450 isoenzymes 50-350 x
Glutathione-S-transferase 100-200 x
Reaction with target molecules
DNA 50-200 x
Components ofsignal ?
transduction pathways
Oncogenes/anti-oncongenes ?
DNA repair > 5 x
Cell growth anddifferentiation Severalfold
Difficulty in Identifying Population
Thresholds forAny Carcinogen
Fromtheabovediscussion, itappears thatexperimental data
aretoolimitedtoconcludetheabsenceorpresenceofthresholds
forcarcinogens, regardlessofthepresumedstageormechanism
ofaction. Humandataareevenmorelimitedregardingthisques-
tion. Thereis,however, abodyofdataconcerninginterindividual
variability inresponsetocarcinogensthatsupportstheassump-
tion oflow-dose linearity. As shown in Table 4, significant in-
terindividual variationhasbeenobservedinhumancellsin vitro
orin vivo intermsofvarious steps inthebiochemical handling
ofcarcinogens. Each ofthese steps orprocesses reflects an in-
terplay between acquired and/or genetic susceptibility (e.g.,
preexistingdisease, nutritional imbalance, viral infection, hor-
monal status, immune surveillance) andenvironmental factors
(e.g., exposuresrelatedtolifestyle, occupation, andtheambient
environment). Whileatfirstglance, severalofthesesteps(e.g.,
DNAbindingandrepair)appeartobeirrelevanttoassessingrisk
oftumor promoters, variation in any step or stage ofthe car-
cinogenic process will, in fact, affectan individual's risk from
promoting agents. For example, the size of the initiated cell
population at risk, dependent upon binding and repair, will
directlydeterminetheeffectofexposuretoatumorpromoter. It
isalsoimmediatelyobviousthatmanyofthesteps(absorption,
activation/deactivation, immmune surveillance) areas relevant
toresponsetopromotingagentsastheyaretoinitiators. Forex-
ample, like PAHs, hormones are oxidized by the cytochrome
P450systemsothatvariationincytochromeP450activitymay
influence riskofbreast cancer (49).
While there are few data that bear specifically on interin-
dividualvariabilityintumorpromotion, recentstudiesinhuman
bronchial cellsinculturehaveshownaseveral-foldvariationin
cell growthanddifferentiation (asevidenced bycolony-forming
efficiency) resulting from treatment with TPA (C. C. Harris,
manuscript inpreparation). Inaddition, inhumanvolunteers, a
markedintersubjectvariationwas seeninTPA-inducedepider-
mal ODC activity levels (50).
The factthatthehumancarcinogenic process extends overa
prolonged period involving multiple stages increases the
likelihoodthatinteractionsmayoccurbetweenmultiplefactors,
includingcombinedactionsofchemicalsandviralagents(6). In-
deed, there isconsiderableexperimental evidenceofsynergistic
interactionbetweengenotoxicagentsandviruses(e.g., PAHand
papillomavirusonmouseskin), betweentumorpromotersand
viruses (e.g., TPAandEpstein-Barr virus intransformation of
human lymphocytes in cell culture) and between cellular
oncogenes activated by chemical carcinogens and viruses (ras
andHPV 16or 18inhumanepithelialcells)(6). Thus, incertain
instances, theassumptionofadditivity onbackgroundmay not
be adequately conservative.
Conclusion
Insummary, themultistageprocessofcancerdevelopmentis
now known to involve both mutagenic and nonmutagenic
mechanisms. Thesemechanismsresultintheinductionofmulti-
ple direct and indirect genetic changes at target oncogenes or
tumor-suppressorgenesaswellasalterations insignaltransduc-
tionpathwaysinvolvedingrowthcontrol. Muchofthediscussion
ofmechanismsfor "nongenotoxic" carcinogensand "tumorpro-
moters" in the context ofpolicy and risk assessment has been
fatally flawedbythelackofconsistentterminologyandanover-
simplificationoftheunderlyingbiologicalprocesses. Thepre-
sent review illustrates the impossibility ofconstructing broad
categoriesaccording tomoreorlessriskymechanismsorstages
ofaction. Thereisaneedtoconsiderboththemultiplicityofac-
tion of single agents and the influence of all agents to which
humansareexposedsimultaneously. Thisso-calledbackground
may include tumor promoting, initiating, or co-carcinogenic
agents. The interindividual variation in cancer risk and in
molecularorbiochemicalresponseamongindividualswithcom-
parable exposure testifies to the complex interplay between
geneticandacquiredfactors. Thisphenomenondeservesspecial
attention inresearch sinceunderstanding the nature ofinterin-
dividual variability and susceptibility is at the heart ofcancer
prevention. Development of biologic markers for studying
nongenotoxicagentsandtumorpromotersin vivoholdspromise
forparallel laboratory andhuman studies. Atthepresenttime,
onemustconcludethatthereisnojustification forsystematically
relaxing standardsofhealthprotectionforcarcinogensbasedon
presumed mechanism orstageofaction.
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